
    
      This is a multicentric, open-label, non-randomized clinical study, evaluating the efficacy
      and the safety of a front-line treatment combining CHOP regimen and rituximab in patients
      aged 60 to 80 years with previously untreated AIL.

      It is anticipated that 25 subjects will be enrolled over 2 years (from 2005 / 2007).Analysis
      performed every 5 patients (based on triangular test).

      The duration of the treatment period is approximately 25 weeks and patients are followed
      until Death.

      The total Duration of the study is expected to be 2.5 years.
    
  